Axxelera

Executive Summary

Axxelera is a German biotechnology company founded in 2019 that specializes in high-density custom peptide microarrays, enabling synthesis and screening of up to 200,000 tailor-made peptides per array. Its platform is applied in epitope mapping, affinity studies, biomarker discovery, and immunoprofiling, primarily serving research in oncology, immunology, and cell therapy. As a service and platform provider, Axxelera addresses the growing demand for high-throughput, customizable peptide screening in drug discovery and diagnostic development. The company is privately held with no disclosed funding or revenue, operating from Munich. Despite limited public information, its technology fills a niche in the peptide microarray market, which is valued for its ability to accelerate identification of immune targets and therapeutic candidates. Axxelera's success hinges on building partnerships and scaling its platform to meet the needs of pharmaceutical and academic clients. The company faces competition from established microarray providers but differentiates itself through customizability and density. Ongoing advancements in immunotherapy and personalized medicine present significant opportunities for Axxelera's technology to gain traction. However, as an early-stage firm, execution risk remains moderate. The next 12–18 months will be critical for demonstrating commercial viability and securing growth capital.

Upcoming Catalysts (preview)

• Q3 2026Launch of high-throughput TCR discovery service70% success
• Q4 2026Strategic partnership with major pharma for oncology biomarker discovery60% success
• Q2 2026Series A funding round to expand operations50% success